Report Detail
Global Erythropoietin Biosimilar Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4742251 |
- 28 September, 2026 |
- Global |
- 123 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Erythropoietin Biosimilar market size was valued at US$ 1649 million in 2025 and is forecast to a readjusted size of US$ 2493 million by 2032 with a CAGR of 6.2% during review period.
Erythropoietin (EPO) is the major glycoprotein hormone regulator of mammalian erythropoiesis , and is produced by kidney and liver in an oxygen-dependent manner. The biological effects of EPO are mediated by the specific erythropoietin receptor (EPOR) on bone marrow erythroblasts, which transmits signals important for both proliferation and differentiation along the erythroid lineage. EPOR is a type 1 single-transmembrane cytokine receptor, and belongs to the homodimerizing subclass which functions as ligand-induced or ligand-stabilized homodimers. EPOR pre-exists as dimers which upon binding of a 34 kDa ligand erythropoietin (Epo), changes its homodimerized state. These conformational changes result in the autophosphorylation of Jak2 kinases that are pre-associated with the receptor. Erythropoietin is necessary to maintain endothelial cells and to promote tumor angiogenesis, hence the dysregulation of EpoR may affect the growth of certain tumors. EpoR signaling prevents neuronal death and ischemic injury.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Erythropoietin Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Erythropoietin Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Erythropoietin Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Erythropoietin Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Erythropoietin Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Erythropoietin Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Erythropoietin Biosimilar market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, VHB Life Sciences, Chengdu Di'Ao Pharmaceutical Group, Chalver Laboratorios, Fresenius Kabi, Neiss Labs, Micro Labs, Zuventus Healthcare, RPG Life Sciences, Unilab, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Erythropoietin Biosimilar market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Market segment by Application
Hematology
Kidney Disorder
Cancer
Others
Major players covered
Pfizer
VHB Life Sciences
Chengdu Di'Ao Pharmaceutical Group
Chalver Laboratorios
Fresenius Kabi
Neiss Labs
Micro Labs
Zuventus Healthcare
RPG Life Sciences
Unilab
Incepta Pharmaceuticals
Genius Biotherapeutics
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Erythropoietin Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Erythropoietin Biosimilar, with price, sales quantity, revenue, and global market share of Erythropoietin Biosimilar from 2021 to 2026.
Chapter 3, the Erythropoietin Biosimilar competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Erythropoietin Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Erythropoietin Biosimilar market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Erythropoietin Biosimilar.
Chapter 14 and 15, to describe Erythropoietin Biosimilar sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Erythropoietin Biosimilar Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Hospital Pharmacy
- 1.3.3 Retail Pharmacy
- 1.3.4 Online Pharmacy
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Erythropoietin Biosimilar Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Hematology
- 1.4.3 Kidney Disorder
- 1.4.4 Cancer
- 1.4.5 Others
- 1.5 Global Erythropoietin Biosimilar Market Size & Forecast
- 1.5.1 Global Erythropoietin Biosimilar Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Erythropoietin Biosimilar Sales Quantity (2021-2032)
- 1.5.3 Global Erythropoietin Biosimilar Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Pfizer
- 2.1.1 Pfizer Details
- 2.1.2 Pfizer Major Business
- 2.1.3 Pfizer Erythropoietin Biosimilar Product and Services
- 2.1.4 Pfizer Erythropoietin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Pfizer Recent Developments/Updates
- 2.2 VHB Life Sciences
- 2.2.1 VHB Life Sciences Details
- 2.2.2 VHB Life Sciences Major Business
- 2.2.3 VHB Life Sciences Erythropoietin Biosimilar Product and Services
- 2.2.4 VHB Life Sciences Erythropoietin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 VHB Life Sciences Recent Developments/Updates
- 2.3 Chengdu Di'Ao Pharmaceutical Group
- 2.3.1 Chengdu Di'Ao Pharmaceutical Group Details
- 2.3.2 Chengdu Di'Ao Pharmaceutical Group Major Business
- 2.3.3 Chengdu Di'Ao Pharmaceutical Group Erythropoietin Biosimilar Product and Services
- 2.3.4 Chengdu Di'Ao Pharmaceutical Group Erythropoietin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Chengdu Di'Ao Pharmaceutical Group Recent Developments/Updates
- 2.4 Chalver Laboratorios
- 2.4.1 Chalver Laboratorios Details
- 2.4.2 Chalver Laboratorios Major Business
- 2.4.3 Chalver Laboratorios Erythropoietin Biosimilar Product and Services
- 2.4.4 Chalver Laboratorios Erythropoietin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Chalver Laboratorios Recent Developments/Updates
- 2.5 Fresenius Kabi
- 2.5.1 Fresenius Kabi Details
- 2.5.2 Fresenius Kabi Major Business
- 2.5.3 Fresenius Kabi Erythropoietin Biosimilar Product and Services
- 2.5.4 Fresenius Kabi Erythropoietin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Fresenius Kabi Recent Developments/Updates
- 2.6 Neiss Labs
- 2.6.1 Neiss Labs Details
- 2.6.2 Neiss Labs Major Business
- 2.6.3 Neiss Labs Erythropoietin Biosimilar Product and Services
- 2.6.4 Neiss Labs Erythropoietin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Neiss Labs Recent Developments/Updates
- 2.7 Micro Labs
- 2.7.1 Micro Labs Details
- 2.7.2 Micro Labs Major Business
- 2.7.3 Micro Labs Erythropoietin Biosimilar Product and Services
- 2.7.4 Micro Labs Erythropoietin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Micro Labs Recent Developments/Updates
- 2.8 Zuventus Healthcare
- 2.8.1 Zuventus Healthcare Details
- 2.8.2 Zuventus Healthcare Major Business
- 2.8.3 Zuventus Healthcare Erythropoietin Biosimilar Product and Services
- 2.8.4 Zuventus Healthcare Erythropoietin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Zuventus Healthcare Recent Developments/Updates
- 2.9 RPG Life Sciences
- 2.9.1 RPG Life Sciences Details
- 2.9.2 RPG Life Sciences Major Business
- 2.9.3 RPG Life Sciences Erythropoietin Biosimilar Product and Services
- 2.9.4 RPG Life Sciences Erythropoietin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 RPG Life Sciences Recent Developments/Updates
- 2.10 Unilab
- 2.10.1 Unilab Details
- 2.10.2 Unilab Major Business
- 2.10.3 Unilab Erythropoietin Biosimilar Product and Services
- 2.10.4 Unilab Erythropoietin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.10.5 Unilab Recent Developments/Updates
- 2.11 Incepta Pharmaceuticals
- 2.11.1 Incepta Pharmaceuticals Details
- 2.11.2 Incepta Pharmaceuticals Major Business
- 2.11.3 Incepta Pharmaceuticals Erythropoietin Biosimilar Product and Services
- 2.11.4 Incepta Pharmaceuticals Erythropoietin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.11.5 Incepta Pharmaceuticals Recent Developments/Updates
- 2.12 Genius Biotherapeutics
- 2.12.1 Genius Biotherapeutics Details
- 2.12.2 Genius Biotherapeutics Major Business
- 2.12.3 Genius Biotherapeutics Erythropoietin Biosimilar Product and Services
- 2.12.4 Genius Biotherapeutics Erythropoietin Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.12.5 Genius Biotherapeutics Recent Developments/Updates
3 Competitive Environment: Erythropoietin Biosimilar by Manufacturer
- 3.1 Global Erythropoietin Biosimilar Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Erythropoietin Biosimilar Revenue by Manufacturer (2021-2026)
- 3.3 Global Erythropoietin Biosimilar Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Erythropoietin Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Erythropoietin Biosimilar Manufacturer Market Share in 2025
- 3.4.3 Top 6 Erythropoietin Biosimilar Manufacturer Market Share in 2025
- 3.5 Erythropoietin Biosimilar Market: Overall Company Footprint Analysis
- 3.5.1 Erythropoietin Biosimilar Market: Region Footprint
- 3.5.2 Erythropoietin Biosimilar Market: Company Product Type Footprint
- 3.5.3 Erythropoietin Biosimilar Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Erythropoietin Biosimilar Market Size by Region
- 4.1.1 Global Erythropoietin Biosimilar Sales Quantity by Region (2021-2032)
- 4.1.2 Global Erythropoietin Biosimilar Consumption Value by Region (2021-2032)
- 4.1.3 Global Erythropoietin Biosimilar Average Price by Region (2021-2032)
- 4.2 North America Erythropoietin Biosimilar Consumption Value (2021-2032)
- 4.3 Europe Erythropoietin Biosimilar Consumption Value (2021-2032)
- 4.4 Asia-Pacific Erythropoietin Biosimilar Consumption Value (2021-2032)
- 4.5 South America Erythropoietin Biosimilar Consumption Value (2021-2032)
- 4.6 Middle East & Africa Erythropoietin Biosimilar Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Erythropoietin Biosimilar Sales Quantity by Type (2021-2032)
- 5.2 Global Erythropoietin Biosimilar Consumption Value by Type (2021-2032)
- 5.3 Global Erythropoietin Biosimilar Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Erythropoietin Biosimilar Sales Quantity by Application (2021-2032)
- 6.2 Global Erythropoietin Biosimilar Consumption Value by Application (2021-2032)
- 6.3 Global Erythropoietin Biosimilar Average Price by Application (2021-2032)
7 North America
- 7.1 North America Erythropoietin Biosimilar Sales Quantity by Type (2021-2032)
- 7.2 North America Erythropoietin Biosimilar Sales Quantity by Application (2021-2032)
- 7.3 North America Erythropoietin Biosimilar Market Size by Country
- 7.3.1 North America Erythropoietin Biosimilar Sales Quantity by Country (2021-2032)
- 7.3.2 North America Erythropoietin Biosimilar Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Erythropoietin Biosimilar Sales Quantity by Type (2021-2032)
- 8.2 Europe Erythropoietin Biosimilar Sales Quantity by Application (2021-2032)
- 8.3 Europe Erythropoietin Biosimilar Market Size by Country
- 8.3.1 Europe Erythropoietin Biosimilar Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Erythropoietin Biosimilar Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Erythropoietin Biosimilar Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Erythropoietin Biosimilar Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Erythropoietin Biosimilar Market Size by Region
- 9.3.1 Asia-Pacific Erythropoietin Biosimilar Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Erythropoietin Biosimilar Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Erythropoietin Biosimilar Sales Quantity by Type (2021-2032)
- 10.2 South America Erythropoietin Biosimilar Sales Quantity by Application (2021-2032)
- 10.3 South America Erythropoietin Biosimilar Market Size by Country
- 10.3.1 South America Erythropoietin Biosimilar Sales Quantity by Country (2021-2032)
- 10.3.2 South America Erythropoietin Biosimilar Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Erythropoietin Biosimilar Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Erythropoietin Biosimilar Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Erythropoietin Biosimilar Market Size by Country
- 11.3.1 Middle East & Africa Erythropoietin Biosimilar Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Erythropoietin Biosimilar Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Erythropoietin Biosimilar Market Drivers
- 12.2 Erythropoietin Biosimilar Market Restraints
- 12.3 Erythropoietin Biosimilar Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Erythropoietin Biosimilar and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Erythropoietin Biosimilar
- 13.3 Erythropoietin Biosimilar Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Erythropoietin Biosimilar Typical Distributors
- 14.3 Erythropoietin Biosimilar Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Erythropoietin Biosimilar. Industry analysis & Market Report on Erythropoietin Biosimilar is a syndicated market report, published as Global Erythropoietin Biosimilar Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Erythropoietin Biosimilar market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
